Table 1. Patient disease characteristics... | American Society of Hematology

Table 1.

Patient disease characteristics and previous treatment regimes

Patient	Age, y	Sex	Stage at diagnosis	Paraprotein type	B₂M (g/L)	Prior therapy	Autograft/no.	Time for relapse after autograft
1	46	M	IIIA	κ free light chain	< 1	None	No	N/A
2	61	M	IIIB	BJκ	29.8	VAD × 3	No	N/A
3	66	F	IIIA	IgGκ	2.5	None	No	N/A
4	56	M	IIIA	IgGκ	5.5	VAD × 4	No	N/A
5	72	M	MGUS	IgGκ	5.9	None	No	N/A
6	61	F	II	IgGκ	8.1	None	No	N/A
7	59	F	I	IgGλ	2.3	VAD × 3	Yes/1	8 months
8	55	M	IIIA	IgG	8.6	CVAMP × 6	Yes/1	18 months
9	41	M	IIIB	IgGκ	4.4	VAMP × 6	Yes/2	8 months
10	55	M	IIIA	NS	1.8	VAD × 5	Yes/1	43 months
4	56	M	IIIA	IgGκ	^*	VAD × 4	Yes/2	11 months
11	41	F	IIIA	IgAλ	3.0	CVAMP × 6	Yes/1	7 months
12	70	M	IIIA	IgAλ	3.5	M + P	No	N/A

Patient	Age, y	Sex	Stage at diagnosis	Paraprotein type	B₂M (g/L)	Prior therapy	Autograft/no.	Time for relapse after autograft
1	46	M	IIIA	κ free light chain	< 1	None	No	N/A
2	61	M	IIIB	BJκ	29.8	VAD × 3	No	N/A
3	66	F	IIIA	IgGκ	2.5	None	No	N/A
4	56	M	IIIA	IgGκ	5.5	VAD × 4	No	N/A
5	72	M	MGUS	IgGκ	5.9	None	No	N/A
6	61	F	II	IgGκ	8.1	None	No	N/A
7	59	F	I	IgGλ	2.3	VAD × 3	Yes/1	8 months
8	55	M	IIIA	IgG	8.6	CVAMP × 6	Yes/1	18 months
9	41	M	IIIB	IgGκ	4.4	VAMP × 6	Yes/2	8 months
10	55	M	IIIA	NS	1.8	VAD × 5	Yes/1	43 months
4	56	M	IIIA	IgGκ	^*	VAD × 4	Yes/2	11 months
11	41	F	IIIA	IgAλ	3.0	CVAMP × 6	Yes/1	7 months
12	70	M	IIIA	IgAλ	3.5	M + P	No	N/A

B2M, beta-2-microglobulin; N/A, not applicable; BJ, Bence-Jones; VAD, vincristine + adriamycin + dexamethasone; IgGκ, immunoglobulin Gκ; MGUS, monoclonal gammopathy of unknown significance; CVAMP, cyclophosphamide + vincristine + adriamycin + methylprednisolone; VAMP, vincristine.

Not performed as sample taken prior to second assay.

View Large

This Feature Is Available To Subscribers Only